Analysts Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $12.33

Tango Therapeutics, Inc. (NASDAQ:TNGX) has received an average rating of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $12.33.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Tango Therapeutics in a report on Monday, April 14th.

Hedge Funds Weigh In On Tango Therapeutics

A number of institutional investors have recently bought and sold shares of TNGX. Dynamic Technology Lab Private Ltd purchased a new position in Tango Therapeutics in the 4th quarter worth about $33,000. Stonebrook Private Inc. purchased a new position in Tango Therapeutics in the 4th quarter worth about $34,000. Ameriprise Financial Inc. purchased a new position in Tango Therapeutics in the 4th quarter worth about $35,000. Sherbrooke Park Advisers LLC purchased a new position in Tango Therapeutics during the 4th quarter valued at about $38,000. Finally, Squarepoint Ops LLC purchased a new position in Tango Therapeutics during the 4th quarter valued at about $40,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Tango Therapeutics Stock Up 1.8%

NASDAQ:TNGX opened at $1.12 on Friday. The business’s 50-day moving average price is $1.51 and its 200 day moving average price is $2.66. The firm has a market cap of $121.08 million, a P/E ratio of -0.95 and a beta of 1.02. Tango Therapeutics has a 52-week low of $1.03 and a 52-week high of $12.02.

Tango Therapeutics (NASDAQ:TNGX) last released its earnings results on Thursday, February 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The firm had revenue of $4.12 million for the quarter, compared to analyst estimates of $7.84 million. Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. Sell-side analysts expect that Tango Therapeutics will post -1.19 EPS for the current year.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.